All In Biotech

Drug Trial Radar · NCT06031844

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Oct 16, 2023

Primary completion

Dec 17, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 24 people with known heart disease and an elevated marker of inflammation, hsCRP.

Conditions

  • Coronary Heart Disease

Interventions

  • DFV890Drug

    Oral film-coated tablets of DFV890 once daily

  • DFV890 PlaceboDrug

    Oral film-coated tablets of DFV890 placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
  2. Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Valley Clinical Trials

    Northridge, California

  • Excel Medical Clinical Trials LLC

    Boca Raton, Florida

  • UF Health Science Center

    Jacksonville, Florida

  • Triad Clinical Trials LLC

    Greensboro, North Carolina

  • Monument Health Clinical Research

    Rapid City, South Dakota

  • Universal Research Group LLC

    Tacoma, Washington

  • Novartis Investigative Site

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.